<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122850">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109172</url>
  </required_header>
  <id_info>
    <org_study_id>0116</org_study_id>
    <nct_id>NCT02109172</nct_id>
  </id_info>
  <brief_title>A 7-Day Cross-over Study of QD and BID TD-4208 in COPD</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of once and twice daily TD-4208 and placebo
      when administered using a jet nebulizer for 7 days in a cross-over design to patients with
      moderate to severe chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weighted mean (0-24) FEV1</measure>
    <time_frame>Following the Day 7 AM dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>56 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC FEV1 and derived weighted means for various timeframes</measure>
    <time_frame>Following Day 7 AM dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Timeframes = (0-4h), (0-6h), (0-24h), (0-12h), and (12-24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial FEV1</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serial FEV1 on Day 7/8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Trough FEV1 on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve 100 mL and 120 mL increase in FEV1 from baseline after the 1st dose</measure>
    <time_frame>Following first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuterol use</measure>
    <time_frame>Days 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rescue albuterol use (puffs per day) over each week of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>TD-4208 44 mcg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208 inhalation solution 44 mcg twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhalation solution twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-4208 175 mcg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD-4208 inhalation solution 175 mcg once daily, placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208</intervention_name>
    <arm_group_label>TD-4208 44 mcg twice daily</arm_group_label>
    <arm_group_label>TD-4208 175 mcg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TD-4208 175 mcg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a negative pregnancy test, and must be prepared to use effective
             contraception if of child-bearing potential

          -  Subject is capable of performing reproducible spirometry maneuvers

          -  Subject has post-bronchodilator FEV1/FVC ratio &lt;0.7

          -  Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD
             Guidelines)

          -  Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80%
             of predicted normal

          -  Subject demonstrates a post-ipratropium FEV1 response ≥ 12% and ≥ 200 mL of
             pre-ipratropium FEV1 response

          -  Subject has a current or past smoking history of at least 10 pack-years.

        Exclusion Criteria:

          -  Subject has a significant respiratory disease or disorder other than COPD that would
             affect the interpretation of data from this study

          -  Subject has a history of reactions or hypersensitivity to inhaled anticholinergic or
             beta-agonist agents

          -  Subject suffers from any medical condition that would preclude the use of inhaled
             anticholinergic agents

          -  Subject has been hospitalized for COPD or pneumonia within 12 weeks.

          -  Subject requires long-term oxygen therapy (&gt;15 hours a day)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Nicholls, MD</last_name>
    <phone>650-808-6400</phone>
    <email>anicholls@theravance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>American Health Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spangenthal, M.D.</last_name>
      <phone>704-342-8143</phone>
    </contact>
    <investigator>
      <last_name>Selwyn Spangenthal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>April 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
